MX2018002487A - Formulaciones de 3-(5-amino-2-metil-4-oxo-4h-quinalozin-3-il)-pipe ridin-2,6-diona. - Google Patents

Formulaciones de 3-(5-amino-2-metil-4-oxo-4h-quinalozin-3-il)-pipe ridin-2,6-diona.

Info

Publication number
MX2018002487A
MX2018002487A MX2018002487A MX2018002487A MX2018002487A MX 2018002487 A MX2018002487 A MX 2018002487A MX 2018002487 A MX2018002487 A MX 2018002487A MX 2018002487 A MX2018002487 A MX 2018002487A MX 2018002487 A MX2018002487 A MX 2018002487A
Authority
MX
Mexico
Prior art keywords
quinazolin
dione
piperidine
oxo
amino
Prior art date
Application number
MX2018002487A
Other languages
English (en)
Inventor
Ghosh Indrajit
Zou Daozhong
walters Colin
Bowen William
Sun Yali
Brumfield Jay
Shen Xiaoxuan
Original Assignee
Celgene Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celgene Corp filed Critical Celgene Corp
Publication of MX2018002487A publication Critical patent/MX2018002487A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/485—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)

Abstract

Se proveen en la presente las composiciones farmacéuticas y formas de dosificación unitarias de Compuesto A (3-(5-amino-2-metil-4-oxo-4H-quinazolin-3-il)-piperidin-2,6-diona ), o un enantiómero o una mezcla de enantiómeros de este, un solvato, hidrato, cocristal, clatrato, polimorfo o sal farmacéuticamente aceptable de este. También se proveen métodos para tratar, controlar o prevenir el cáncer con las formas de dosificación descritas en la presente.
MX2018002487A 2015-08-27 2016-08-26 Formulaciones de 3-(5-amino-2-metil-4-oxo-4h-quinalozin-3-il)-pipe ridin-2,6-diona. MX2018002487A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562210923P 2015-08-27 2015-08-27
PCT/US2016/048905 WO2017035443A1 (en) 2015-08-27 2016-08-26 Pharmaceutical compositions comprising 3-(5-amino-2-methyl-4-oxo-4h-quinazolin-3-yl)-piperidine-2,6-dione

Publications (1)

Publication Number Publication Date
MX2018002487A true MX2018002487A (es) 2018-06-15

Family

ID=56883865

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018002487A MX2018002487A (es) 2015-08-27 2016-08-26 Formulaciones de 3-(5-amino-2-metil-4-oxo-4h-quinalozin-3-il)-pipe ridin-2,6-diona.

Country Status (17)

Country Link
US (1) US10064863B2 (es)
EP (1) EP3340969B1 (es)
JP (1) JP2018525422A (es)
KR (1) KR20180039084A (es)
CN (1) CN107921004A (es)
AU (1) AU2016310340A1 (es)
BR (1) BR112018003335A2 (es)
CA (1) CA2996641A1 (es)
CL (1) CL2018000489A1 (es)
CO (1) CO2018002545A2 (es)
EA (1) EA201890585A1 (es)
EC (1) ECSP18023544A (es)
ES (1) ES2865289T3 (es)
HK (1) HK1252415A1 (es)
IL (1) IL257666A (es)
MX (1) MX2018002487A (es)
WO (1) WO2017035443A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017004532A1 (en) 2015-07-02 2017-01-05 Celgene Corporation Combination therapy for treatment of hematological cancers and solid tumors
AU2016364753A1 (en) 2015-12-02 2018-06-14 Celgene Corporation Cycling therapy using 3-(5-amino-2-methyl-4-oxo-4H-quinazolin-3-yl)-piperidine-2,6-dione

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7498171B2 (en) 2002-04-12 2009-03-03 Anthrogenesis Corporation Modulation of stem and progenitor cell differentiation, assays, and uses thereof
HUE026827T2 (en) 2006-09-26 2016-07-28 Celgene Corp 5-substituted quinazolinone derivatives as anticancer agents
BR112013023277A2 (pt) * 2011-03-11 2017-06-27 Celgene Corp métodos de tratamento de câncer usando 3-(5-amino-2-metil-4-oxo-4h-quinazolin-3-il)-piperidibna-2,6-diona
CA2829570C (en) * 2011-03-11 2019-05-07 Celgene Corporation Solid forms of 3-(5-amino-2-methyl-4-oxo-4h-quinazolin-3-yl)-piperidine-2,6-dione, and their pharmaceutical compositions and uses
US20150196562A1 (en) * 2014-01-15 2015-07-16 Celgene Corporation Formulations of 3-(5-amino-2-methyl-4-oxo-4h-quinazolin-3-yl)-piperidine-2,6-dione

Also Published As

Publication number Publication date
CO2018002545A2 (es) 2018-07-10
JP2018525422A (ja) 2018-09-06
EP3340969B1 (en) 2021-02-17
ES2865289T3 (es) 2021-10-15
CL2018000489A1 (es) 2018-08-03
CN107921004A (zh) 2018-04-17
US20170056323A1 (en) 2017-03-02
KR20180039084A (ko) 2018-04-17
EA201890585A1 (ru) 2018-11-30
EP3340969A1 (en) 2018-07-04
HK1252415A1 (zh) 2019-05-24
ECSP18023544A (es) 2018-04-30
BR112018003335A2 (pt) 2018-09-25
WO2017035443A1 (en) 2017-03-02
CA2996641A1 (en) 2017-03-02
US10064863B2 (en) 2018-09-04
AU2016310340A1 (en) 2018-03-15
IL257666A (en) 2018-04-30

Similar Documents

Publication Publication Date Title
CY1124669T1 (el) ΑΝΤΙ-ΟΙΣΤΡΟΓΟΝΙΚΑ ΦΑΡΜΑΚΑ ΤΕΤΡΑΫΔΡΟ-1Η-ΠΥΡΙΔΟ[3,4-b]INΔOΛIOY
PH12019500395A1 (en) Amino-pyrrolopyrimidinone compounds and methods of use thereof
PH12015500212A1 (en) Methods of treating cancer using 3-(4-((4-(morpholinomethyl)benzyl)oxy)-1-oxoixoindolin-2-yl)piperidine-2,6-dione
MX2017010477A (es) Compuestos triciclicos y usos de los mismos en medicina.
UA117976C2 (uk) Сполуки амінопіримідинілу як інгібітори jak
EA033689B9 (ru) Ингибиторы g12c kras
NZ721617A (en) Heterocyclic compounds
MX2021005207A (es) Formulaciones de 2-(terc-butilamino)-4-((1r,3r,4r)-3-hidroxi-4-met ilciclohexilamino)-pirimidina-5-carboxamida.
EP4275707A3 (en) Formulations of 2-(4-chlorophenyl)-n-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-2,2-difluoroacetamide
PH12016500301A1 (en) Formulations of (s)-3-(4-((4-(morpholinomethyl)benzyloxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione
PH12019501639A1 (en) Jaki selective inhibitors
PH12016501517A1 (en) Tetrazolone-substituted dihydropyridinone mgat2 inhibitors
CY1124251T1 (el) Παραγωγα καρβοξαμιδιου
MX2016014946A (es) Derivados de carboxamida.
EA201891289A1 (ru) Циклическая терапия с применением 3-(5-амино-2-метил-4-оксо-4h-хиназолин-3-ил)пиперидин-2,6-диона
MX2018002487A (es) Formulaciones de 3-(5-amino-2-metil-4-oxo-4h-quinalozin-3-il)-pipe ridin-2,6-diona.
TW201713630A (en) Substituted quinazoline compounds and methods of use thereof
MX2015015290A (es) Compuestos furanona como inhibidores de quinasa.
MX2018015990A (es) Compuestos terapeuticos.
PH12016502247A1 (en) Carboxamide derivatives